No Data
No Data
Xiangxue Pharmaceuticals: Semi-Annual Report 2024
Xiangxue Pharmaceuticals: 2024 Semi-Annual Report Summary
Xiangxue Pharmaceutical (300147.SZ) released its performance for the first half of the year, with a net loss of 0.135 billion yuan, and the loss expanded.
Xiangxue Pharmaceutical (300147.SZ) released its 2024 interim report, with revenue of 1.097 billion yuan...
Xiangxue Pharmaceutical (300147.SZ): Net loss of 0.135 billion yuan in the first half of the year, with an expanded loss compared to the same period last year.
Xiangxue Pharmaceutical (300147.SZ) announced its semi-annual report for 2024, with operating revenue of 1.097 billion yuan, a 8.72% decrease compared to the same period last year; net income attributable to shareholders of the listed company was -0.135 billion yuan, with an increased loss compared to the same period last year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.108 billion yuan; basic earnings per share was -0.2 yuan.
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) Price Is Right But Growth Is Lacking After Shares Rocket 25%
The function of xiangxue pharmaceutical (300147.SZ) product Huoxiang Zhengqi mixture is to release exterior and transform dampness, regulate qi and harmonize the middle burner.
Xiangxue Pharmaceutical (300147.SZ) stated on its investor interaction platform on July 31st that the company's product, Huoxiang Zhengqi Oral Liquid, functions to disperse exterior pathogenic factors and resolve dampness, regulate qi and harmonize the middle. It is used for summer dampness cold, headache, body heaviness and chest tightness, or cold and fever with abdominal distension, vomiting, and diarrhea.
No Data